期刊文献+

miR-23b-3p对肝核因子4的靶基因及效用分析 被引量:2

Target gene and effect analysis of miR-23b-3p on hepatocyte nuclear factor 4
下载PDF
导出
摘要 目的探索miR-23b-3p是否以肝核因子4作为靶基因并下调apo(a)表达,为降高脂蛋白(a)血症提供新的思路。方法用Targetscan在线工具对miR-23b-3p与调控LPA基因的转录因子肝核因子4(HNF4)进行靶基因分析;在JM109细胞中使用荧光素酶报告系统对miR-23b-3p与调控筛选调控LPA基因的转录因子HNF4进行靶基因进行验证实验;用RT-PCR检测Hep G2细胞apo(a)mRNA表达水平。结果 Targetscan生物信息学分析工具表明HNF4G可作为miR-23b-3p的靶基因,荧光素酶报告系统转染miR-23b-3p处理组细胞裂解后荧光强度显著低于对照组,miR-23b-3p的抑制剂可抑制其作用,验证了HNF4G可作为miR-23b-3p的靶基因。转染miR-23b-3p可抑制Hep G2细胞apo(a)mRNA的表达。结论 miR-23b-3p以HNF4为其靶基因,并下调Hep G2细胞apo(a)的表达。 Objective To investigate whether or not hepatocyte nuclear factor 4( HNF4) is the target gene of miR-23b-3p,and down-regulating effect of miR-23b-3p on apolipoprotein( a) [apo( a) ] expression,providing a new idea for reducing high concentration lipoprotein( a). Methods Target genes in miR-23b-3p and hepatocyte nuclear factor 4 were analyzed by Targetgene,an online bioinformatics tools,and tested by dual luciferase reporter assays in JM109 cell,RT-PCR was used to measure the expression level of apo( a) in Hep G2 cell. Results Targetgene scanning result indicated that HNF4 mRNA could be target gene of a miR-23b-3p;,compared with the control group,the fluorescence density of the group with miR-23b-3p transfection in dual luciferase reporter assays system,decreased significantly; miR-23b-3p inhibitor could inhibit the role of miR-23b-3p,which verified that HNF4 is a target gene of miR-23b-3p; and apo( a) mRNA expression decreased after miR-23b-3p transfection in Hep G2 cell. Conclusion HNF4 is a target gene of miR-23b-3pand it can decrease apo( a) mRNA expression.
出处 《湘南学院学报(医学版)》 2015年第1期1-4,共4页 Journal of Xiangnan University(Medical Sciences)
基金 国家自然科学基金项目(81070221) 江苏省博士后科研资助基金(1302095B) 湖南省卫生厅课题(B2013-034 B2011-054)资助
关键词 载脂蛋白(a) 靶基因 miR-23b-3p 肝核因子4 apolipoprotein target gene miR-23b-3p hepatocyte nuclear factor 4
  • 相关文献

参考文献7

  • 1Langer C, Tambyrayah B, Thedieck S, et al. Testing for Lipoprotein (a) Concentration and Apolipoprotein (a) Phe- notypes: Method Standardization and Pediatric Reference Values[ J]. Semin Thromb Hemost, 2011,37 (7) : 810 - 813.
  • 2Nguyen Tr, Ellefson RD, Hodge DO, et al. Predictive value of electrophoretically detected lipoprotein (a) for coronary heart disease and cerebmvascular disease in a communitybased co- hort of 9936 men and women[ J ]. Circulation, 1997,96 ( 5 ) :1390-1397.
  • 3Kraft HG, Kronenberg F, Utermann G. Genetic variants in Lp (a) lipoprotein and coronary disease [ J]. N Engl J Med, 2010,362(12) : 1146,1147-1148.
  • 4Konerman M, Kulkami K, Toth PP, et al. Evidence of depend- ence of lipoprotein (a) on triglyceride and high-density li- poproteinMetabolism[ J ]. J Clin Lipidol, 2012,6 ( 1 ) : 27 - 32.
  • 5Chennamsetty I, Claudel T, Kostner KM, et al. Famesoid X receptor represses hepatic human APOA gene expression [J]. J Clin Invest, 2011,121 (9) :3724-3734.
  • 6Puckey LH, Knight BL. Sequence and functional changes in a putative enhancer region upstream of the apolipoprotein(a) gene [ J ]. Atherosclerosis, 2003,166 ( 1 ) : 119-127.
  • 7Hixson JE, Jett C, Birnbaum S. Identification of promoter se- quences in the 5" untranslated region of the baboon apoli- poprotein(a) gene [ J ]. J Lipid Res, 1996,37 ( 11 ) : 2324- 2331.

同被引文献12

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部